Case File Banner 24

Real-World Step Therapy Case: A Challenging DME Patient

Show Description +

How do you manage a patient with DME whose inability to arrive at the clinic may be adversely affecting her disease course? Jordan M. Graff, MD, reviews the case of a patient who fits this description, and discuss the value of retinal dryness and non-steroidal approaches to DME therapy. In this particular case, Dr. Graff begins with samples of faricimab (Vabysmo, Genentech), moves to step therapy–mandated bevacizumab (Avastin, Genentech), then onto bevacizumab in one eye and faricimab in the contralateral eye, and then finally onto insurance-approved faricimab.

Posted: 10/03/2023

Up Next

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD


Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

How do you manage a patient with DME whose inability to arrive at the clinic may be adversely affecting her disease course? Jordan M. Graff, MD, reviews the case of a patient who fits this description, and discuss the value of retinal dryness and non-steroidal approaches to DME therapy. In this particular case, Dr. Graff begins with samples of faricimab (Vabysmo, Genentech), moves to step therapy–mandated bevacizumab (Avastin, Genentech), then onto bevacizumab in one eye and faricimab in the contralateral eye, and then finally onto insurance-approved faricimab.

Posted: 10/03/2023


Please log in to leave a comment.